| Title |
Catatonia in Patients with Autism: Prevalence and Management
|
|---|---|
| Published in |
CNS Drugs, February 2014
|
| DOI | 10.1007/s40263-014-0143-9 |
| Pubmed ID | |
| Authors |
Luigi Mazzone, Valentina Postorino, Giovanni Valeri, Stefano Vicari |
| Abstract |
Although recent studies have shown that catatonia can occur in patients with autism spectrum disorders (ASDs), the overlap of the behavioral features between these disorders raises many diagnostic challenges. In fact, in clinical practice it is common to misinterpret catatonic symptoms, including mutism, stereotypic speech, repetitive behaviors, echolalia, posturing, mannerisms, purposeless agitation and rigidity, as features of ASDs. The current medical treatment algorithm for catatonia in ASDs recommends the use of benzodiazepines. Electroconvulsive therapy (ECT) is indicated when patients are unresponsive, or insufficiently responsive, to benzodiazepines. Other pharmacological options are also described for the treatment of catatonic patients resistant to benzodiazepines and ECT, and there is evidence for the effectiveness of a psychological treatment, co-occurring with medical treatments, in order to support the management of these patients. In this article we provide a summary of studies exploring catatonia in ASDs and our clinical experience in the management and treatment of this syndrome through the presentation of three brief case studies. Moreover, we review the mechanisms underlying symptoms of catatonia in ASDs, as well as the diagnostic challenges, providing an outline for the management and treatment of this syndrome in this clinical population. |
Mendeley readers
The data shown below were compiled from readership statistics for 121 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | <1% |
| Unknown | 120 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 20 | 17% |
| Student > Master | 17 | 14% |
| Student > Ph. D. Student | 12 | 10% |
| Student > Postgraduate | 10 | 8% |
| Student > Bachelor | 10 | 8% |
| Other | 23 | 19% |
| Unknown | 29 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 35 | 29% |
| Psychology | 16 | 13% |
| Neuroscience | 8 | 7% |
| Social Sciences | 6 | 5% |
| Agricultural and Biological Sciences | 5 | 4% |
| Other | 14 | 12% |
| Unknown | 37 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2017.
All research outputs
#5,480,331
of 22,751,628 outputs
Outputs from CNS Drugs
#525
of 1,305 outputs
Outputs of similar age
#64,015
of 307,216 outputs
Outputs of similar age from CNS Drugs
#9
of 22 outputs
Altmetric has tracked 22,751,628 research outputs across all sources so far. Compared to these this one has done well and is in the 75th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,305 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has gotten more attention than average, scoring higher than 59% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,216 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 79% of its contemporaries.
We're also able to compare this research output to 22 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 59% of its contemporaries.